Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | EVP, Chief Scientific Officer | August 31, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IONIS PHARMACEUTICALS INC
Report date August 31, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,128 |
Reported balance
After 2026-08-31 transaction · row 1
1 source rowRow 1 · 2026-08-31 · Other · Acquired 110 · Balance 60,128 F1: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 18, 2017 Filed Oct 20, 2017 21:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 12,250 | $10.29 | $126,052.50 |
DisclosureSEC source: 0000874015-17-000064 · edgar.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/27/2017. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/27/2017. Read SEC document |
| July 24, 2017 Filed Jul 27, 2017 00:03 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000052 · edgar.xml · derivative · entry 3 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 10,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2017 Filed Jul 27, 2017 00:03 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 10,000 | $59.29 | $592,900.00 |
DisclosureSEC source: 0000874015-17-000052 · edgar.xml · nonDerivative · entry 2 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,041 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/27/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/27/2015. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.25 to $59.33, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| July 24, 2017 Filed Jul 27, 2017 00:03 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 10,000 | $10.29 | $102,900.00 |
DisclosureSEC source: 0000874015-17-000052 · edgar.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/27/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/27/2015. Read SEC document |
| July 01, 2017 Filed Jul 3, 2017 21:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 253 | $40.66 | $10,285.84 |
DisclosureSEC source: 0000874015-17-000043 · edgar.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,041 F1 · kind: Reporting 253 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July1, 2017. These 253 shares may not be sold until January 2, 2018. F1 · shares: Reporting 253 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July1, 2017. These 253 shares may not be sold until January 2, 2018. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 00:25 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000025 · edgar.xml · derivative · entry 3 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,250 Underlying: Common Stock · 5,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 00:25 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,000 | $55.00 | $275,000.00 |
DisclosureSEC source: 0000874015-17-000025 · edgar.xml · nonDerivative · entry 2 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,788 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/27/2017. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/27/2017. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 00:25 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 5,000 | $10.29 | $51,450.00 |
DisclosureSEC source: 0000874015-17-000025 · edgar.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/27/2017. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/27/2017. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:37 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 623 | $46.29 | $28,838.67 |
DisclosureSEC source: 0000874015-17-000014 · edgar.xml · nonDerivative · entry 8 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,788 F8 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. F8 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:37 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 512 | $46.29 | $23,700.99 |
DisclosureSEC source: 0000874015-17-000014 · edgar.xml · nonDerivative · entry 6 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,817 F6 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. F6 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:37 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 733 | $46.29 | $33,930.57 |
DisclosureSEC source: 0000874015-17-000014 · edgar.xml · nonDerivative · entry 4 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,018 F4 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. F4 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:37 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 553 | $46.29 | $25,598.37 |
DisclosureSEC source: 0000874015-17-000014 · edgar.xml · nonDerivative · entry 2 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,876 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 30, 2013. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 30, 2013. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:37 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 1,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000014 · edgar.xml · derivative · entry 13 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,779 Underlying: Common Stock · 1,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F8 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:37 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 1,311 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000014 · edgar.xml · derivative · entry 12 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,620 Underlying: Common Stock · 1,311 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F6 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:37 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000014 · edgar.xml · derivative · entry 11 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:37 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 1,415 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000014 · edgar.xml · derivative · entry 10 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,415 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 30, 2013. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:37 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 7,537 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000014 · edgar.xml · derivative · entry 9 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,537 Underlying: Common Stock · 7,537 shares Expires not disclosed F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F10 · derivative.exercise_date: Grant 1/15/2017 to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2021. The RSU is vested as to 0 shares on January 15, 2017. F10 · derivative.expiration_date: Grant 1/15/2017 to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2021. The RSU is vested as to 0 shares on January 15, 2017. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:37 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000014 · edgar.xml · nonDerivative · entry 7 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2016. F7 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2016. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:37 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,311 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000014 · edgar.xml · nonDerivative · entry 5 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2015. F5 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2015. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:37 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000014 · edgar.xml · nonDerivative · entry 3 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2014. F3 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2014. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:37 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,415 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000014 · edgar.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 30, 2013. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 30, 2013. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:32 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 45,225 | $0.00 Strike: $47.34 | $0.00 |
DisclosureSEC source: 0000874015-17-000003 · edgar.xml · derivative · entry 2 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,225 Underlying: Common Stock · 45,225 shares Expires 2024-01-02 F2 · derivative.exercise_date: Grant of 1/3/2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/3/2018. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 11,306 shares per year. Following this transaction, the option was exercisable as to 0 on 1/3/2017. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 23:32 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 211 | $20.76 | $4,379.73 |
DisclosureSEC source: 0000874015-17-000003 · edgar.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,014 F1 · kind: Reporting 211 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 211 shares may not be sold until July 2, 2017. F1 · shares: Reporting 211 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 211 shares may not be sold until July 2, 2017. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 22,805 | $0.00 Strike: $11.27 | $0.00 |
DisclosureSEC source: 0000874015-16-000143 · edgar.xml · derivative · entry 5 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,805 shares Expires 2017-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 17,805 | $38.54 | $686,204.70 |
DisclosureSEC source: 0000874015-16-000143 · edgar.xml · nonDerivative · entry 4 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,803 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/16/2016. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/16/2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.50 to $38.60, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 17,805 | $11.27 | $200,662.35 |
DisclosureSEC source: 0000874015-16-000143 · edgar.xml · nonDerivative · entry 3 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/16/2016. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/16/2016. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,000 | $34.08 | $170,400.00 |
DisclosureSEC source: 0000874015-16-000143 · edgar.xml · nonDerivative · entry 2 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,803 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/16/2016. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/16/2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.30, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 5,000 | $11.27 | $56,350.00 |
DisclosureSEC source: 0000874015-16-000143 · edgar.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/16/2016. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/16/2016. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 23:22 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $11.27 | $0.00 |
DisclosureSEC source: 0000874015-16-000142 · edgar.xml · derivative · entry 3 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,805 Underlying: Common Stock · 5,000 shares Expires 2017-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 23:22 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,000 | $34.00 | $170,000.00 |
DisclosureSEC source: 0000874015-16-000142 · edgar.xml · nonDerivative · entry 2 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,803 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/17. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/16/17. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/17. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/16/17. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 23:22 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 5,000 | $11.27 | $56,350.00 |
DisclosureSEC source: 0000874015-16-000142 · edgar.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/17. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/16/17. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/17. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/16/17. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.